GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Equity-to-Asset

Lixte Biotechnology Holdings (FRA:8640) Equity-to-Asset : 0.93 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lixte Biotechnology Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3.66 Mil. Lixte Biotechnology Holdings's Total Assets for the quarter that ended in Dec. 2023 was €3.95 Mil.

The historical rank and industry rank for Lixte Biotechnology Holdings's Equity-to-Asset or its related term are showing as below:

FRA:8640' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.49   Med: 0.92   Max: 0.96
Current: 0.93

During the past 13 years, the highest Equity to Asset Ratio of Lixte Biotechnology Holdings was 0.96. The lowest was 0.49. And the median was 0.92.

FRA:8640's Equity-to-Asset is ranked better than
91.57% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs FRA:8640: 0.93

Lixte Biotechnology Holdings Equity-to-Asset Historical Data

The historical data trend for Lixte Biotechnology Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Equity-to-Asset Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 0.96 0.94 0.93 0.93

Lixte Biotechnology Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.94 0.87 0.94 0.93

Competitive Comparison of Lixte Biotechnology Holdings's Equity-to-Asset

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Equity-to-Asset falls into.



Lixte Biotechnology Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lixte Biotechnology Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3.663/3.951
=

Lixte Biotechnology Holdings's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=3.663/3.951
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lixte Biotechnology Holdings  (FRA:8640) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Lixte Biotechnology Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (FRA:8640) Business Description

Traded in Other Exchanges
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines